The Metastatic Brain Tumor drugs in development market research report provides comprehensive information on the therapeutics under development for Metastatic Brain Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Metastatic Brain Tumor. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Metastatic Brain Tumor and features dormant and discontinued products.
GlobalData tracks 67 drugs in development for Metastatic Brain Tumor by 59 companies/universities/institutes. The top development phase for Metastatic Brain Tumor is preclinical with 24 drugs in that stage. The Metastatic Brain Tumor pipeline has 65 drugs in development by companies and two by universities/ institutes. Some of the companies in the Metastatic Brain Tumor pipeline products market are: Wayshine Biopharma, Praesidia Biotherapeutics and Jubilant Therapeutics.
The key targets in the Metastatic Brain Tumor pipeline products market include Cyclin Dependent Kinase 4, Cyclin Dependent Kinase 6, and DNA.
The key mechanisms of action in the Metastatic Brain Tumor pipeline product include Cyclin Dependent Kinase 4 Inhibitor with five drugs in Phase II. The Metastatic Brain Tumor pipeline products include 12 routes of administration with the top ROA being Oral and nine key molecule types in the Metastatic Brain Tumor pipeline products market including Small Molecule, and Gene-Modified Cell Therapy.
Metastatic Brain Tumor overview
Metastatic brain tumors, also known as secondary brain tumors, occur when cancer cells spread to the brain from a primary cancer elsewhere in the body. These tumors are more common than primary brain tumors, arising from cancers originating in other organs such as the lungs, breast, colon, or skin (melanoma) and then migrating to the brain through the bloodstream or lymphatic system. When cancer cells reach the brain and form tumors, they disrupt normal brain function and can cause a variety of symptoms, including headaches, seizures, nausea or vomiting, changes in vision or hearing, weakness or numbness in the extremities, changes in cognitive abilities or personality, and difficulty with balance or coordination. Diagnosis of metastatic brain tumors typically involves imaging tests such as MRI or CT scans to visualize the tumors and determine their location, size, and number. Biopsies may be performed to confirm the origin of the tumors and guide treatment decisions.
For a complete picture of Metastatic Brain Tumor’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
